Scorpius has extensive experience in developing recovery and purification processes for a wide variety of recombinant biotherapeutics including proteins, enzymes, immunotoxins, monoclonal antibodies, protein-based vaccines, and cellular therapy exosomal products.
Scorpius BioManufacturing's advanced protein characterization capabilities, including conformational and structural analyses via biophysical techniques, allow for the performance of critical structure-function studies as well as the assessment of refolding recombinant proteins expressed as insoluble inclusion bodies.
The extensive downstream purification process development capabilities offered at Scorpius' CDMO biomanufacturing facilities allow us to develop reproducible, scalable manufacturing processes to accelerate a client's clinical development program. We take an integrated approach to process development that links together PD and analytical development teams to ensure a development strategy that accelerates timelines and reduces risk.
